NYSE:BMYBristol-Myers Squibb Stock Price, Forecast & News

$60.89

+0.68 (+1.13 %)

(As of 06/4/2020 04:00 PM ET)

Add

Compare

Today's Range

$59.82

Now: $60.89▼

$61.09

50-Day Range

$59.46

MA: $61.27▼

$64.09

52-Week Range

$42.48

Now: $60.89▼

$68.34

Volume13.48 million shs

Average Volume16.13 million shs

Market Capitalization$137.78 billion

P/E Ratio75.17

Dividend Yield2.99%

Beta0.72

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company's products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis. It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd. The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Beat the Market (BTM) Rank^™

3.4 Analyst's Opinion

Consensus Rating
Bristol-Myers Squibb has received a consensus rating of Buy. The company's average rating score is 2.79, and is based on 11 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $68.17, Bristol-Myers Squibb has a potential upside of 12.0% from its current price of $60.89.
Amount of Analyst Coverage
Bristol-Myers Squibb has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.6 Community Rank

Outperform Votes
Bristol-Myers Squibb has received 1,010 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Bristol-Myers Squibb has received 917 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Bristol-Myers Squibb has received 52.41% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Bristol-Myers Squibb and other stocks. Vote “Outperform” if you believe BMY will outperform the S&P 500 over the long term. Vote “Underperform” if you believe BMY will underperform the S&P 500 over the long term. You may vote once every thirty days.

5.0 Dividend Strength

Dividend Leadership
Bristol-Myers Squibb is a leading dividend payer. It pays a dividend yield of 2.99%, putting its dividend yield in the top 25% of dividend-paying stocks.
Dividend Growth
Bristol-Myers Squibb has been increasing its dividend for 10 years.
Dividend Coverage
The dividend payout ratio of Bristol-Myers Squibb is 38.38 %. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Bristol-Myers Squibb will have a dividend payout ratio of 24.49 % next year. This indicates that Bristol-Myers Squibb will be able to sustain or increase its dividend.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bristol-Myers Squibb insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $2,726,495.00 in company stock.
Percentage Held by Insiders
Only 0.14% of the stock of Bristol-Myers Squibb is held by insiders.
Percentage Held by Institutions
74.17% of the stock of Bristol-Myers Squibb is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Bristol-Myers Squibb are expected to grow by 19.51% in the coming year, from $6.15 to $7.35 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bristol-Myers Squibb is 75.17, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 16.19.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bristol-Myers Squibb is 75.17, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 28.56.
Price to Earnings Growth Ratio
Bristol-Myers Squibb has a PEG Ratio of 1.18. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Bristol-Myers Squibb has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

2.52 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NYSE

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNYSE:BMY

Previous Symbol

CUSIP11012210

CIK14272

Webwww.bms.com

Phone212-546-4000

Debt

Debt-to-Equity Ratio0.86

Current Ratio1.66

Quick Ratio1.51

Price-To-Earnings

Trailing P/E Ratio75.17

Forward P/E Ratio9.90

P/E Growth1.18

Sales & Book Value

Annual Sales$26.15 billion

Price / Sales5.27

Cash Flow$4.41 per share

Price / Cash Flow13.81

Book Value$23.20 per share

Price / Book2.62

Profitability

EPS (Most Recent Fiscal Year)$4.69

Net Income$3.44 billion

Net Margins3.08%

Return on Equity30.06%

Return on Assets10.96%

Miscellaneous

Employees30,000

Outstanding Shares2,262,690,000

Market Cap$137.78 billion

Next Earnings Date7/23/2020 (Estimated)

OptionableOptionable

Receive BMY News and Ratings via Email

Sign-up to receive the latest news and ratings for BMY and its competitors with MarketBeat's FREE daily newsletter.

Bristol-Myers Squibb (NYSE:BMY) Frequently Asked Questions

How has Bristol-Myers Squibb's stock been impacted by COVID-19 (Coronavirus)?

Bristol-Myers Squibb's stock was trading at $56.51 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, BMY stock has increased by 7.8% and is now trading at $60.89. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Bristol-Myers Squibb?

14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bristol-Myers Squibb in the last year. There are currently 3 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Bristol-Myers Squibb.

When is Bristol-Myers Squibb's next earnings date?

Bristol-Myers Squibb is scheduled to release its next quarterly earnings announcement on Thursday, July 23rd 2020. View our earnings forecast for Bristol-Myers Squibb.

How were Bristol-Myers Squibb's earnings last quarter?

Bristol-Myers Squibb Co (NYSE:BMY) released its quarterly earnings data on Thursday, May, 7th. The biopharmaceutical company reported $1.72 earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of $1.49 by $0.23. The biopharmaceutical company earned $10.78 billion during the quarter, compared to analysts' expectations of $10.04 billion. Bristol-Myers Squibb had a return on equity of 30.06% and a net margin of 3.08%. Bristol-Myers Squibb's revenue was up 82.1% on a year-over-year basis. During the same period in the previous year, the firm earned $1.10 EPS. View Bristol-Myers Squibb's earnings history.

How often does Bristol-Myers Squibb pay dividends? What is the dividend yield for Bristol-Myers Squibb?

Bristol-Myers Squibb declared a quarterly dividend on Monday, March 2nd. Stockholders of record on Friday, April 3rd will be given a dividend of $0.45 per share on Friday, May 1st. This represents a $1.80 annualized dividend and a yield of 2.96%. The ex-dividend date of this dividend is Thursday, April 2nd. View Bristol-Myers Squibb's dividend history.

What guidance has Bristol-Myers Squibb issued on next quarter's earnings?

Bristol-Myers Squibb issued an update on its FY21 earnings guidance on Thursday, May, 7th. The company provided EPS guidance of $7.15-7.45 for the period, compared to the Thomson Reuters consensus estimate of $7.39.

What price target have analysts set for BMY?

14 analysts have issued 12 month price targets for Bristol-Myers Squibb's stock. Their forecasts range from $50.00 to $88.00. On average, they anticipate Bristol-Myers Squibb's stock price to reach $68.17 in the next year. This suggests a possible upside of 12.0% from the stock's current price. View analysts' price targets for Bristol-Myers Squibb.

Has Bristol-Myers Squibb been receiving favorable news coverage?

Headlines about BMY stock have trended somewhat positive this week, InfoTrie Sentiment reports. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Bristol-Myers Squibb earned a media sentiment score of 1.6 on InfoTrie's scale. They also assigned press coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news aboutBristol-Myers Squibb.

Who are some of Bristol-Myers Squibb's key competitors?

Some companies that are related to Bristol-Myers Squibb include Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Zoetis (ZTS), Allergan (AGN), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Zogenix (ZGNX) and Corcept Therapeutics (CORT). View all competitors.

What other stocks do shareholders of Bristol-Myers Squibb own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bristol-Myers Squibb investors own include AbbVie (ABBV), AT&T (T), Pfizer (PFE), Verizon Communications (VZ), Bank of America (BAC), NVIDIA (NVDA), Intel (INTC), Johnson & Johnson (JNJ), Cisco Systems (CSCO) and CVS Health (CVS).

Who are Bristol-Myers Squibb's key executives?

Bristol-Myers Squibb's management team includes the following people:

Dr. Giovanni Caforio, Chairman & CEO (Age 54)
Mr. Charles A. Bancroft, Exec. VP of Global Bus. Operations & CFO (Age 59)
Dr. Thomas J. Lynch Jr., Exec. VP & Chief Scientific Officer (Age 58)
Ms. Sandra Leung Esq., Exec. VP & Gen. Counsel (Age 58)
Mr. Paul von Autenried, Sr. VP & Chief Information Officer (Age 57)

What is Bristol-Myers Squibb's stock symbol?

Bristol-Myers Squibb trades on the New York Stock Exchange (NYSE) under the ticker symbol "BMY."

Who are Bristol-Myers Squibb's major shareholders?

Bristol-Myers Squibb's stock is owned by a number of institutional and retail investors. Top institutional shareholders include Wellington Management Group LLP (3.34%), Invesco Ltd. (1.00%), Primecap Management Co. CA (0.96%), Morgan Stanley (0.80%), Legal & General Group Plc (0.68%) and Loomis Sayles & Co. L P (0.60%). Company insiders that own Bristol-Myers Squibb stock include Adam Dubow, John E Elicker, Karen Murphy Santiago, Louis S Schmukler, Robert J Bertolini and Theodore R Samuels II. View institutional ownership trends for Bristol-Myers Squibb.

Which major investors are selling Bristol-Myers Squibb stock?

BMY stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Wellington Management Group LLP, Two Sigma Advisers LP, Invesco Ltd., Morgan Stanley, Skandinaviska Enskilda Banken AB publ, Primecap Management Co. CA, and APG Asset Management N.V.. Company insiders that have sold Bristol-Myers Squibb company stock in the last year include Adam Dubow, John E Elicker, and Louis S Schmukler. View insider buying and selling activity for Bristol-Myers Squibb.

Which major investors are buying Bristol-Myers Squibb stock?

BMY stock was bought by a variety of institutional investors in the last quarter, including Swiss National Bank, Sumitomo Mitsui Trust Holdings Inc., First Trust Advisors LP, Lord Abbett & CO. LLC, Connor Clark & Lunn Investment Management Ltd., Advisor Group Holdings Inc., Conning Inc., and Artemis Investment Management LLP. Company insiders that have bought Bristol-Myers Squibb stock in the last two years include Robert J Bertolini, and Theodore R Samuels II. View insider buying and selling activity for Bristol-Myers Squibb.

How do I buy shares of Bristol-Myers Squibb?

Shares of BMY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Bristol-Myers Squibb's stock price today?

One share of BMY stock can currently be purchased for approximately $60.89.

How big of a company is Bristol-Myers Squibb?

Bristol-Myers Squibb has a market capitalization of $137.78 billion and generates $26.15 billion in revenue each year. The biopharmaceutical company earns $3.44 billion in net income (profit) each year or $4.69 on an earnings per share basis. Bristol-Myers Squibb employs 30,000 workers across the globe.

What is Bristol-Myers Squibb's official website?

The official website for Bristol-Myers Squibb is www.bms.com.

How can I contact Bristol-Myers Squibb?

Bristol-Myers Squibb's mailing address is 430 E. 29TH STREET 14 FLOOR, NEW YORK NY, 10016. The biopharmaceutical company can be reached via phone at 212-546-4000 or via email at [email protected]

This page was last updated on 6/4/2020 by MarketBeat.com Staff